Update - EpiPen® 300mcg adrenaline (epinephrine) autoinjectors supply - 13 Feb 2018
ASCIA has now updated information on the EpiPen® 300mcg shortage
Mylan has advised that normal stock of EpiPen® 300mcg adrenaline autoinjectors is expected to be available in pharmacies by late February 2018. A process has been put in place by Mylan to ensure those at risk of anaphylaxis have access to the treatment they may need.
Currently there is no shortage of EpiPen® Jr 150mcg adrenaline autoinjectors. If a pharmacy is out of stock of EpiPen® Jr, the pharmacist should contact their wholesaler/s to obtain stock. If there are any problems they should phone Mylan on 1800 274 276.
Individuals will be able to access one in-date adrenaline autoinjector until the shortage resolves by late February 2018. It is important to note that a device expiring in February 2018 does not actually expire until the end of that month, not the start of that month. Patients should retain their recently expired autoinjector/s (see information below).
In the case of anaphylaxis, patients and/or carers should follow instructions on their ASCIA Action Plan www.allergy.org.au/anaphylaxis (Give EpiPen® and call an ambulance by phoning 000 AU or 111 NZ).
Patients and/or carers who require support should contact the national patient support organisations, Allergy & Anaphylaxis Australia (phone 1300 728 000 or contact us) or Allergy New Zealand www.allergy.org.nz
Use of expired adrenaline autoinjectors
Whilst the use of an expired adrenaline autoinjector is not ideal, research suggests that recently expired devices retain potency. Therefore, if no other adrenaline autoinjector is available, use of a recently expired device to treat anaphylaxis is advised, as stated on the ASCIA website: www.allergy.org.au/health-professionals/anaphylaxis-resources/adrenaline-autoinjector-storage-expiry-and-disposal